CoChat
Sign Up
Cited by 559Hormonal and reproductive studiesBone health and osteoporosis researchMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.

Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men

Behre, Hermann M., Kliesch, Sabine, Leifke, Eckhard, Link, Thomas M., Nieschlag, Eberhard·1997·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem.82.8.4163
Open this paper in CoChat — free account

Abstract

In both men and women, a decrease in bone mineral density (BMD) is a major symptom of hypogonadism. Although the effects of estrogens on osteoporosis in women are well documented, comparatively little is known about the effects of long term testosterone substitution on BMD in hypogonadal men. Therefore, we studied BMD in 72 hypogonadal patients (37 men with primary and 35 men with secondary hypogonadism) under testosterone substitution therapy that continued for up to 16 yr. Thirty-two of these men were also seen before initiation of therapy. At annual intervals, trabecular BMD of the lumbar spine was measured by quantitative computed tomography, a true volumetric and reproducible method for long term serial BMD measurements. Serum levels of testosterone increased to the normal range in all androgen-treated hypogonadal men. The most significant increase in BMD was seen during the first year of testosterone treatment in previously untreated patients, when BMD increased from 95.2 ± 5.9 to 120.0 ± 6.1 mg/cm3 hydroxyapatite (mean ± se). Long term testosterone treatment maintained BMD in the age-dependent reference range in all 72 hypogonadal men, independent of the type of hypogonadism. Transdermal testosterone patches applied to the scrotum were as effective in normalizing BMD as im testosterone enanthate injections. In summary, testosterone therapy increases BMD in hypogonadal men regardless of age. The greatest increase is seen during the first year of treatment in previously untreated patients with low initial BMD. In hypogonadal men, BMD can be normalized and maintained in the normal range by continuous, long term testosterone substitution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem.82.8.4163

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E.
Affiliations
University of Münster (DE)
Corresponding author
Nieschlag, Eberhard
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
1997-08-01
Volume
82
Issue
8
Pages
2386-2390
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem.82.8.4163
OpenAlex
W2163320305
Semantic Scholar
8c83f4c5d1798e90b32e461c6499e89accd38287
Cited by
559
References
49
Citations by year
2026: 7 · 2025: 10 · 2024: 11 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 11 · 2019: 18 · 2018: 14 · 2017: 12 · 2016: 8 · 2015: 18 · 2014: 19 · 2013: 18 · 2012: 26
FWCI
17.40
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
testosterone replacement therapy, bone mineral density, hypogonadism, male hypogonadism, hypergonadotropic hypogonadism, secondary hypogonadism, osteoporosis, testosterone enanthate, long-term treatment outcomes
MeSH terms
Administration, Cutaneous, Administration, Oral, Adolescent, Adult, Aged, Humans, Hypogonadism, Injections, Intramuscular, Male, Middle Aged, Regression Analysis, Testosterone, Bone Density

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review